These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33287235)

  • 1. Colombian Contributions Fighting Leishmaniasis: A Systematic Review on Antileishmanials Combined with Chemoinformatics Analysis.
    Sánchez-Suárez J; Bernal FA; Coy-Barrera E
    Molecules; 2020 Dec; 25(23):. PubMed ID: 33287235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution, treatment outcome and genetic diversity of Leishmania species in military personnel from Colombia with cutaneous leishmaniasis.
    Correa-Cárdenas CA; Pérez J; Patino LH; Ramírez JD; Duque MC; Romero Y; Cantillo-Barraza O; Rodríguez O; Alvarado MT; Cruz C; Méndez C
    BMC Infect Dis; 2020 Dec; 20(1):938. PubMed ID: 33297972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antileishmanial Activities of Medicinal Herbs and Phytochemicals In Vitro and In Vivo: An Update for the Years 2015 to 2021.
    Hassan AA; Khalid HE; Abdalla AH; Mukhtar MM; Osman WJ; Efferth T
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Systematic Review of Curcumin and its Derivatives as Valuable Sources of Antileishmanial Agents.
    Albalawi AE; Alanazi AD; Sharifi I; Ezzatkhah F
    Acta Parasitol; 2021 Sep; 66(3):797-811. PubMed ID: 33770343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of total phenolic fraction derived from extra virgin olive oil for its antileishmanial activity.
    Koutsoni OS; Karampetsou K; Kyriazis ID; Stathopoulos P; Aligiannis N; Halabalaki M; Skaltsounis LA; Dotsika E
    Phytomedicine; 2018 Aug; 47():143-150. PubMed ID: 30166099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening.
    Ortiz D; Guiguemde WA; Hammill JT; Carrillo AK; Chen Y; Connelly M; Stalheim K; Elya C; Johnson A; Min J; Shelat A; Smithson DC; Yang L; Zhu F; Guy RK; Landfear SM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006157. PubMed ID: 29287089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings.
    Santana W; de Oliveira SSC; Ramos MH; Santos ALS; Dolabella SS; Souto EB; Severino P; Jain S
    Chem Biodivers; 2021 Sep; 18(9):e2100336. PubMed ID: 34369662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing O-substituted nifuroxazide analogues against Leishmania: Synthesis, in vitro efficacy, and hit/lead identification.
    Badenhorst GD; Kannigadu C; Aucamp J; N'Da DD
    Eur J Pharm Sci; 2022 Sep; 176():106242. PubMed ID: 35732232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis.
    Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA
    Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoblot analysis of Leishmania panamensis antigens in sera of patients with American cutaneous leishmaniasis.
    Isaza DM; Restrepo M; Mosca W
    J Clin Microbiol; 1997 Dec; 35(12):3043-7. PubMed ID: 9399491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antileishmanial activity of Artemisia annua L. leaf powder and its potential usefulness in the treatment of uncomplicated cutaneous leishmaniasis in humans.
    Mesa LE; Vasquez D; Lutgen P; Vélez ID; Restrepo AM; Ortiz I; Robledo SM
    Rev Soc Bras Med Trop; 2017; 50(1):52-60. PubMed ID: 28327802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
    Castro MDM; Cossio A; Velasco C; Osorio L
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005515. PubMed ID: 28379954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Update on Natural Antileishmanial Treatment Options from Plants, Fungi and Algae.
    Koko WS; Al Nasr IS; Khan TA; Schobert R; Biersack B
    Chem Biodivers; 2022 Jan; 19(1):e202100542. PubMed ID: 34822224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miltefosine for new world cutaneous leishmaniasis.
    Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
    Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
    Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
    Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antileishmanial activity of synthetic analogs of the naturally occurring quinolone alkaloid N-methyl-8-methoxyflindersin.
    Torres Suarez E; Granados-Falla DS; Robledo SM; Murillo J; Upegui Y; Delgado G
    PLoS One; 2020; 15(12):e0243392. PubMed ID: 33370295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eugenol derivatives with 1,2,3-triazole moieties: Oral treatment of cutaneous leishmaniasis and a quantitative structure-activity relationship model for their leishmanicidal activity.
    Teixeira RR; Rodrigues Gazolla PA; Borsodi MPG; Castro Ferreira MM; Andreazza Costa MC; Costa AV; Cabral Abreu Grijó B; Rossi Bergmann B; Lima WP
    Exp Parasitol; 2022 Jul; 238():108269. PubMed ID: 35526574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
    Eissa MM; Amer EI; El Sawy SM
    Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How I Approach Leishmaniasis: Diagnosis and Treatment in the United States.
    Ness TE; Martin-Blais R; Weatherhead JE
    J Pediatric Infect Dis Soc; 2022 Dec; 11(11):525-532. PubMed ID: 36043874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future Prospects in the Treatment of Parasitic Diseases: 2-Amino-1,3,4-Thiadiazoles in Leishmaniasis.
    Serban G
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31010226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.